MGC Pharmaceuticals is a biopharma company with a “Nature to Medicine” core strategy. It is at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company’s mission is to build an innovative, global bio-pharma company providing standardised, affordable plant derived medicines of the highest regulatory compliance for targeted global markets. MGC Pharmaceuticals is able to help diverse groups of people through the research and development of pharmaceutical products that increase patients’ quality of life. Through its successful research focus it currently holds pipelines for phytocannabinoid-based medications and unique formulations (Phytomedicines), both proprietary and for third parties, all under GMP certified regulations and facilities. This includes our ability to create API (Active Pharmaceutical Ingredient) of various phytocannabinoids alongside compounding to be used in the pharmaceutical treatment and research globally. MGC has developed an efficient production pipeline of phytocannabinoid derived medications, with multiple products currently being prescribed to patients, and products currently in clinical development and testing. It has facilities all over the world, including Australia, Slovenia and the UK.